Dan Leonard
Stock Analyst at UBS
(2.97)
# 1,171
Out of 4,667 analysts
272
Total ratings
53.85%
Success rate
5.6%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Neutral | $25 → $20 | $13.20 | +51.55% | 3 | Oct 30, 2024 | |
| DHR Danaher | Maintains: Buy | $309 → $305 | $231.32 | +31.85% | 16 | Oct 23, 2024 | |
| CYRX Cryoport | Maintains: Neutral | $7 → $9 | $6.50 | +38.57% | 2 | Oct 18, 2024 | |
| MEDP Medpace Holdings | Downgrades: Neutral | $420 → $350 | $335.34 | +4.37% | 1 | Sep 27, 2024 | |
| CERT Certara | Upgrades: Buy | $16 | $9.49 | +68.69% | 9 | Sep 27, 2024 | |
| GH Guardant Health | Maintains: Buy | $32 → $40 | $30.54 | +30.98% | 8 | Aug 21, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $295 → $300 | $194.97 | +53.87% | 12 | Jul 23, 2024 | |
| BIO Bio-Rad Laboratories | Maintains: Buy | $420 → $385 | $322.92 | +19.22% | 19 | May 8, 2024 | |
| BIO.B Bio-Rad Laboratories | Maintains: Buy | $420 → $385 | $334.85 | +14.98% | 19 | May 8, 2024 | |
| RVTY Revvity | Downgrades: Neutral | $105 → $125 | $113.66 | +9.98% | 1 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $70.17 | +14.02% | 10 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $17.38 | +101.38% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $150 | $131.49 | +14.08% | 21 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $133.37 | +49.96% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $4.81 | +128.69% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $169.36 | -58.67% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $90 | $53.43 | +68.44% | 9 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $24 | $20.20 | +18.84% | 6 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $620 | $509.59 | +21.67% | 13 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $255 | $189.34 | +34.68% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $4.41 | +58.73% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $345 | $365.89 | -5.71% | 12 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $209.52 | +24.10% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $162.39 | -10.71% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $78.68 | +14.39% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $62 | $42.22 | +46.39% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $238.68 | +42.45% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $85 → $90 | $54.38 | +65.50% | 9 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $18.80 | +27.69% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,350 → $1,500 | $1,176.57 | +27.49% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $15.39 | +127.42% | 12 | Aug 14, 2019 |
10x Genomics
Oct 30, 2024
Maintains: Neutral
Price Target: $25 → $20
Current: $13.20
Upside: +51.55%
Danaher
Oct 23, 2024
Maintains: Buy
Price Target: $309 → $305
Current: $231.32
Upside: +31.85%
Cryoport
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $6.50
Upside: +38.57%
Medpace Holdings
Sep 27, 2024
Downgrades: Neutral
Price Target: $420 → $350
Current: $335.34
Upside: +4.37%
Certara
Sep 27, 2024
Upgrades: Buy
Price Target: $16
Current: $9.49
Upside: +68.69%
Guardant Health
Aug 21, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $30.54
Upside: +30.98%
IQVIA Holdings
Jul 23, 2024
Maintains: Buy
Price Target: $295 → $300
Current: $194.97
Upside: +53.87%
Bio-Rad Laboratories
May 8, 2024
Maintains: Buy
Price Target: $420 → $385
Current: $322.92
Upside: +19.22%
Bio-Rad Laboratories
May 8, 2024
Maintains: Buy
Price Target: $420 → $385
Current: $334.85
Upside: +14.98%
Revvity
Jan 16, 2024
Downgrades: Neutral
Price Target: $105 → $125
Current: $113.66
Upside: +9.98%
Dec 7, 2023
Initiates: Buy
Price Target: $80
Current: $70.17
Upside: +14.02%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $17.38
Upside: +101.38%
Aug 16, 2023
Maintains: Outperform
Price Target: $160 → $150
Current: $131.49
Upside: +14.08%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $133.37
Upside: +49.96%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $4.81
Upside: +128.69%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $169.36
Upside: -58.67%
Aug 2, 2023
Maintains: Neutral
Price Target: $75 → $90
Current: $53.43
Upside: +68.44%
Jul 31, 2023
Reiterates: Neutral
Price Target: $24
Current: $20.20
Upside: +18.84%
Jul 13, 2023
Upgrades: Outperform
Price Target: $620
Current: $509.59
Upside: +21.67%
May 12, 2023
Maintains: Outperform
Price Target: $260 → $255
Current: $189.34
Upside: +34.68%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $4.41
Upside: +58.73%
Aug 25, 2022
Initiates: Neutral
Price Target: $345
Current: $365.89
Upside: -5.71%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $209.52
Upside: +24.10%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $162.39
Upside: -10.71%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $78.68
Upside: +14.39%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $60 → $62
Current: $42.22
Upside: +46.39%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $238.68
Upside: +42.45%
Nov 2, 2021
Maintains: Equal-Weight
Price Target: $85 → $90
Current: $54.38
Upside: +65.50%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $18.80
Upside: +27.69%
Jul 30, 2021
Maintains: Equal-Weight
Price Target: $1,350 → $1,500
Current: $1,176.57
Upside: +27.49%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $15.39
Upside: +127.42%